🎯 𝐢𝐜𝐨𝐛𝐫𝐚𝐢𝐧 𝐚𝐫𝐢𝐚 has received 𝐅𝐃𝐀 𝐜𝐥𝐞𝐚𝐫𝐚𝐧𝐜𝐞 as the 𝐟𝐢𝐫𝐬𝐭 𝐚𝐧𝐝 𝐨𝐧𝐥𝐲 𝐦𝐞𝐝𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐢𝐜𝐞 for detecting, diagnosing, and monitoring amyloid-related imaging abnormalities (ARIA). A revolutionary step in 𝐀𝐥𝐳𝐡𝐞𝐢𝐦𝐞𝐫’s care! 👏 Congratulations to the whole icometrix team 👏
❗️🚨❗️🚨❗️ 𝗕𝗥𝗘𝗔𝗞𝗜𝗡𝗚 𝗡𝗘𝗪𝗦 I am incredibly excited to announce the FDA clearance of icobrain aria, as the 𝗳𝗶𝗿𝘀𝘁 𝗮𝗻𝗱 𝗼𝗻𝗹𝘆 𝗙𝗗𝗔-𝗰𝗹𝗲𝗮𝗿𝗲𝗱 𝗺𝗲𝗱𝗶𝗰𝗮𝗹 𝗱𝗲𝘃𝗶𝗰𝗲 for the detection, diagnosis, and monitoring of amyloid-related imaging abnormalities (ARIA), a potentially harmful side effect of new amyloid-targeting therapies for Alzheimer's disease. This is also a major milestone for the field of neurology, as icobrain aria is 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝗺𝗽𝘂𝘁𝗲𝗿-𝗮𝗶𝗱𝗲𝗱 𝗱𝗲𝘁𝗲𝗰𝘁𝗶𝗼𝗻 (𝗖𝗔𝗗𝗲) 𝗮𝗻𝗱 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀 (𝗖𝗔𝗗𝘅) 𝗱𝗲𝘃𝗶𝗰𝗲 cleared by the FDA! I am so proud of our icometrix team and all our collaborators, partners, and supporters. We are impacting care. We are impacting safety. We are impacting people’s lives. 🧠 Please find some of my thoughts in the article below 👇. The importance of this breakthrough is also summarized in the press release, which can be found in the comments: 👉 Prof. Stephen Salloway: “Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer’s disease but they are associated with a risk of brain swelling and hemorrhage called ARIA. New standardized tools are needed, such as icobrain aria, to assist radiologists and treating clinicians in detecting and managing ARIA to optimize patient safety. I am excited that icobrain aria has received FDA approval, clearing the way for wider use in clinical practice.” 👉 Prof. Jeffrey Cummings: “icobrain aria was thoroughly evaluated in large reader studies. It was demonstrated that the assistance of AI significantly improved radiologists’ ability to detect and classify ARIA, boosting both diagnostic sensitivity and accuracy, and adding a critical safety option for patients undergoing amyloid-targeting therapies.” 👉 Mr. George Vradenburg: “For families facing Alzheimer’s disease, the new disease-modifying therapies have brought renewed hope. But to help as many people as possible, we do need to standardize the care pathways and make sure we have access to cognitive tests, blood biomarkers, and imaging exams that can ensure a timely diagnosis and a safe drug prescription. Thanks to the FDA clearance of icobrain aria, Alzheimer’s therapies are more accessible and safer for patients, as it provides clinicians with the tools they need to make informed, effective treatment decisions.” Biogen Eli Lilly and Company Eisai US Eisai Co., Ltd. Eisai EMEA Roche Novartis beMedTech Alzheimer's Association® Alzheimer's Society American Society of Neuroradiology American Society of Functional Neuroradiology Radiological Society of North America (RSNA) American Academy of Neurology Alzheimer's Drug Discovery Foundation #Alzheimers #ARIA #lecanemab #leqembi #donanemab #kisunla #aduhelm #aducanumab #artificialintelligence #AI #MRI #dementia #neuroradiology #neuroimaging #radiology #neurology #RSNA24